到平台还是不到平台:在临床开发早期对抗体制剂的战略考虑
Tim Menzen1, Kristian Le Vay1, Andrea Arsiccio1
1Coriolis Pharma Research GmbH, Fraunhoferstr. 18B, 82152 Martinsried, Germany.
Journal of pharmaceutical sciences
|November 3, 2025
概括
配方科学家可以评估蛋白质的稳定性,以确保平台配方适合治疗性蛋白质,如单克隆抗体 (mAbs). 这种基于风险的方法指导了临床前发展和稳定性研究的决策.
科学领域:
- 生物制药开发 生物制药开发
- 蛋白质稳定性 蛋白质稳定性
- 配方科学科学 配方科学
背景情况:
- 治疗性蛋白质配方需要通过广泛的实验来确定最佳稳定条件.
- 使用已确立的类似蛋白质配方的平台方法,如单克隆抗体 (mAbs),可能会导致临床使用的稳定性不足.
- 配方性评估通过评估蛋白质稳定性和配方兼容性来弥合发现和临床前开发.
研究的目的:
- 为实施单克隆抗体 (mAbs) 平台配方策略提供基于风险的框架.
- 为了指导配方科学家在基于蛋白质性质的平台配方或扩展的预配方选之间做出决定.
- 概述评估蛋白质可配制性和进行稳定性研究的方法.
主要方法:
- 评估候选蛋白质的生物物理特性,以评估其稳定性.
- 考虑到配方条件 (缓冲类型,pH,辅助剂) 与蛋白质稳定性相关.
- 采用系统的预制和储存稳定性研究,使用平台分析方法.
主要成果:
- 可制定性评估为基于风险的平台制定决策提供了关键数据.
- 确定蛋白质是否适合平台配方或需要进一步选.
- 能够做出明智的选择,以确保蛋白质的结构,体和化学稳定性.
结论:
- 基于风险的方法,包括可制定性评估,对于成功制定mAb平台至关重要.
- 这一策略减轻了将平台配方应用于新蛋白候选物的风险.
- 通过优化配方选择和稳定性测试,促进高效的临床前开发.
关键词:
开发能力评估 开发能力评估评价可编制性的评估配方开发 配方开发单克隆抗体是一种单克隆抗体.平台配方的制定方法预制剂选 预制剂选 预制剂选 预制剂选蛋白质的稳定性 蛋白质的稳定性稳定性研究研究.更多相关视频
07:53Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study
Published on: August 16, 2019
9.8K
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
15.2K
相关概念视频
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
227
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
227
01:25Antibody Structure and Classes
8.2K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
8.2K
01:10Antibody Structure
65.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.2K
01:31Hybridoma Technology
17.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.2K
01:28Preclinical Development: Overview
5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
01:26Antibody Actions
2.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K